ORIGINAL ARTICLE   

Minerva Biotecnologica 2020 December;32(4):139-42

DOI: 10.23736/S1120-4826.19.02598-9

Copyright © 2019 EDIZIONI MINERVA MEDICA

language: English

Predicted peptide-based MHC-I, MHC-II, CTL and B-cell epitopes of MUC-1 by immunoinformatics methods: a clue for novel multi-epitope vaccine development against breast cancer

Pejman HASHEMZADEH ¹, Vajihe GHORBANZADEH ², Hassan DARIUSHNEJAD ^{1, 2} ✉

¹ Department of Medical Biotechnology, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran; ² Razi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran

BACKGROUND: Breast cancer (BC) is one of the most common types of women malignancy. Multi-epitope vaccines are new hopes for treatment of this cancer. MUC-1 is a tumor associated antigen that focused for multi-epitope vaccine development in case of BC.
METHODS: Here, primary data from a computation analysis of this glycoprotein to find potential MHC-I, MHC-II, CTL and B-cell epitopes are described using immunoinformatics tools.
RESULTS: According to the results, 1156VPGWGIALL984 corresponding to HLA-B0702 and HLA-A0101 alleles for MHC-I epitopes, 1209YPTYHTHGR1118 corresponding to DRB1*13 and DQB1*06 alleles for MHC-II epitops, 1122NQYKTEAAS45 for CTL epitopes and 1204HPMSEYPTYHTHGRYV896 for B-cell epitopes are the peptides with the best binding affinity.
CONCLUSIONS: These data may be useful for further multi-epitope vaccine development.

KEY WORDS: Breast neoplasms; Epitopes; Vaccines, synthetic; Mucin-1